stanozolol has been researched along with Genetic Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazargan, N; Farhoudi, A; Mahmoudi, M; Pourpak, Z | 1 |
| Glickman, RS; Karlis, V; Kinney, L; Stern, R | 1 |
| Agostoni, A; Cicardi, M | 1 |
1 review(s) available for stanozolol and Genetic Diseases
| Article | Year |
|---|---|
Hereditary angioedema: case report and review of management.
Topics: Anabolic Agents; Angioedema; Blood Transfusion; Child; Complement Activation; Complement C1 Inactivator Proteins; Dental Care for Chronically Ill; Female; Genetic Diseases, Inborn; Humans; Plasma; Stanozolol; Tooth Extraction | 1997 |
2 other study(ies) available for stanozolol and Genetic Diseases
| Article | Year |
|---|---|
Two related cases of primary complement deficiency.
Topics: Adult; Anti-Bacterial Agents; Complement C3; Danazol; Dyspnea; Edema; Female; Genetic Diseases, Inborn; Glomerulonephritis; Humans; Male; Meningitis, Pneumococcal; Pedigree; Stanozolol | 2003 |
Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Autoimmune Diseases; Causality; Child; Complement C1 Inactivator Proteins; Danazol; Female; Follow-Up Studies; Genetic Diseases, Inborn; Hospitals, University; Humans; Italy; Male; Middle Aged; Phenotype; Stanozolol; Treatment Outcome | 1992 |